Boehringer Ingelheim to Cap Out-of-Pocket Cost for Inhalers at $35

Higher costs per claim, coupled with an increased number of patients using specialty drugs, has contributed to higher spend.

In this week's episode of Tuning In to the C-Suite podcast, MHE's Briana Contreras spoke with Dr. Rob Kowal, chief medical officer of the Cardiac Rhythm and Heart Failure division at Medtronic. The two discussed how remote monitoring and IoT is changing healthcare and how remote technology is also gaining a wide-spread adoption to monitor patients at home who have chronic conditions like heart failure, chronic obstructive pulmonary disease and diabetes.

Duvyzat was approved in March 2024 and works to reduce the inflammation and loss of muscle experienced by patients with Duchenne muscular dystrophy.

For patients with interstitial lung disease (ILD), a subsequent diagnosis of pulmonary hypertension substantially increases utilization of healthcare resources as well as costs.

Epysqli is a monoclonal antibody that is approved to treat two rare conditions that break down red blood cells.